Skip to content
Aspivix logo
  • News
  • About us
  • Contact
  • Distribution Network
  • English
    • Français
    • Italiano
    • Deutsch
Buy Now
Search
Close
  • For Healthcare Professionals
  • For Women
  • Find your OBGYN
  • Resources
  • News
  • About us
  • Contact
  • Distribution Network
  • English
    • Français
    • Italiano
    • Deutsch
Buy Now
  • For Healthcare Professionals
  • For Women
  • Find your OBGYN
  • Resources
Aspivix logo
Home > News

Press Contact
For media enquiries, please reach out to: contact@aspivix.com

All
  • All
  • Blog
  • In the media
  • Press releases
74

No more trauma on Intrauterine Contraceptive Devices

February 11, 2021
Read More about No more trauma on Intrauterine Contraceptive Devices
23

January Intentions: Getting to Know your Cervix

January 7, 2021
In recognition of Cervical Cancer Awareness month, we would like to join the conversation and spread awareness around this very crucial part of the female reproductive system. As women, it’s important to be...
Read More about January Intentions: Getting to Know your Cervix
75

Innovation in women’s health comes in small doses

December 30, 2020
Read More about Innovation in women’s health comes in small doses
76

5 Top Emerging Reproductive Health Startups

December 30, 2020
Read More about 5 Top Emerging Reproductive Health Startups
77

Les premières données cliniques tombent pour Aspivix, et elles sont réjouissantes !

December 17, 2020
Read More about Les premières données cliniques tombent pour Aspivix, et elles sont réjouissantes !
78

ASPIVIX’s Press Release featured in Investhirozon.eu

December 14, 2020
Read More about ASPIVIX’s Press Release featured in Investhirozon.eu
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
Loading... loader
Scroll to learn more

Company

  • Home

Contact

Global Headquarters
Aspivix SA
Route de la Corniche 8
1066 Epalinges
Switzerland

contact@aspivix.com

Legal

  • Cookie Policy
  • Privacy Statement
  • Imprint
  • Disclaimer

Follow

Carevix® is currently FDA-Cleared for US market, CE-Marked for EU market and authorized in UK and Brazil. Available for commercialization. It has not been licensed or approved for sale in other markets.

© 2026 Aspivix SA. All rights reserved. Aspivix™, and Carevix® are trademarks or registered trademarks of Aspivix SA and/or its subsidiaries.

Where are you located?

Europe
United States

Where are you located?

Europe
United States